Latanoprost vs Bimatoprost — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Prostaglandin Analog

Latanoprost

Brand: XALATAN

First FDA approval: 2010-11-15

Prostaglandin Analog

Bimatoprost

Brand: DURYSTA

First FDA approval: 2009-01-26

Lowest NADACAcquisition cost floor across all NDCs

$1.20Per unit

$7.19Per unit

Average NADACAcross all dosage forms and strengths

$12.26Up to $108.44

$24.98Up to $103.28

Generic manufacturersActive ANDA holders — FDA Orange Book

88 total ANDAs filed

912 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$204.7MFull year

$969.1MFull year

Part D claims (CY24)Total fills, all strengths

16.6M4.9M beneficiaries

2.2M643K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$12Per claim, all NDCs

$449Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

1Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

5Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes8 manufacturers

Yes9 manufacturers